Tjønnfjord GE - Search Results

1

High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.

Berentsen S, Randen U, Vågan AM, Hjorth-Hansen H, Vik A, Dalgaard J, Jacobsen EM, Thoresen AS, Beiske K, Tjønnfjord GE. Berentsen S, et al. Among authors: tjonnfjord ge. Blood. 2010 Oct 28;116(17):3180-4. doi: 10.1182/blood-2010-06-288647. Epub 2010 Jul 15. Blood. 2010. PMID: 20634373 Free article. Clinical Trial.

2

No response to cladribine in five patients with chronic cold agglutinin disease.

Berentsen S, Tjønnfjord GE, Shammas FV, Bergheim J, Hammerstrøm J, Langholm R, Ulvestad E. Berentsen S, et al. Among authors: tjonnfjord ge. Eur J Haematol. 2000 Jul;65(1):88-90. doi: 10.1034/j.1600-0609.2000.9l201.x. Eur J Haematol. 2000. PMID: 10914950 No abstract available.

3

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. Dearden CE, et al. Among authors: tjonnfjord ge. Blood. 2001 Sep 15;98(6):1721-6. doi: 10.1182/blood.v98.6.1721. Blood. 2001. PMID: 11535503 Free article. Clinical Trial.

4

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.

Berentsen S, Tjønnfjord GE, Brudevold R, Gjertsen BT, Langholm R, Løkkevik E, Sørbø JH, Ulvestad E. Berentsen S, et al. Among authors: tjonnfjord ge. Br J Haematol. 2001 Oct;115(1):79-83. doi: 10.1046/j.1365-2141.2001.03078.x. Br J Haematol. 2001. PMID: 11722415 Free article.

5

[Paroxysmal nocturnal hemoglobinuria--a rare disease with many faces].

Dalgaard J, Brinch L, Tjønnfjord GE. Dalgaard J, et al. Among authors: tjonnfjord ge. Tidsskr Nor Laegeforen. 2002 Feb 10;122(4):374-8. Tidsskr Nor Laegeforen. 2002. PMID: 11915665 Free article. Norwegian.

6

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, Ghanima W, Shammas FV, Tjønnfjord GE. Berentsen S, et al. Among authors: tjonnfjord ge. Blood. 2004 Apr 15;103(8):2925-8. doi: 10.1182/blood-2003-10-3597. Epub 2003 Dec 30. Blood. 2004. PMID: 15070665 Free article. Clinical Trial.

7

Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE. Berentsen S, et al. Among authors: tjonnfjord ge. Haematologica. 2006 Apr;91(4):460-6. Haematologica. 2006. PMID: 16585012

8

Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies.

Micci F, Panagopoulos I, Tjønnfjord GE, Kolstad A, Delabie J, Beiske K, Heim S. Micci F, et al. Among authors: tjonnfjord ge. Virchows Arch. 2007 May;450(5):559-65. doi: 10.1007/s00428-007-0407-6. Epub 2007 Apr 4. Virchows Arch. 2007. PMID: 17406891

9

Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Berentsen S, Beiske K, Tjønnfjord GE. Berentsen S, et al. Among authors: tjonnfjord ge. Hematology. 2007 Oct;12(5):361-70. doi: 10.1080/10245330701445392. Hematology. 2007. PMID: 17891600 Free PMC article. Review.

10

B-lymphocytes as targets for therapy in chronic cold agglutinin disease.

Berentsen S, Ulvestad E, Tjønnfjord GE. Berentsen S, et al. Among authors: tjonnfjord ge. Cardiovasc Hematol Disord Drug Targets. 2007 Sep;7(3):219-27. doi: 10.2174/187152907781745279. Cardiovasc Hematol Disord Drug Targets. 2007. PMID: 17896962 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page